A Comprehensive Review of Monoclonal Gammopathy of Undetermined Significance - Scorecard - MDSpire

A Comprehensive Review of Monoclonal Gammopathy of Undetermined Significance

Approximately 3% to 4% of the population over the age of 50 is diagnosed with monoclonal gammopathy of undetermined significance (MGUS). It carries a lifelong risk of progression to multiple myeloma and lymphoma, requiring risk-adapted monitoring by multidisciplinary teams.

  • By

  • Kimberly Noonan

  • Kevin Brigle

  • Charise Gleason

  • Carrie Bellerive

  • Mary Steinbach

  • Deborah Doss

  • March 4, 2026

  • 17 min

Share

Clinical Scorecard: A Comprehensive Review of Monoclonal Gammopathy of Undetermined Significance

At a Glance

CategoryDetail
Condition
Key MechanismsCharacterized by the presence of monoclonal proteins in plasma without end-organ damage (defined by CRAB criteria).
Target Population
Care Setting

Key Highlights

  • MGUS is often an incidental finding in 3-4% of the population over 50 years old.
  • The risk of progression to multiple myeloma is approximately 1% to 1.5% per year for non-IgM MGUS.
  • Monitoring is essential; treatment is not typically required unless there is organ involvement.
  • Advanced practice providers are crucial for the management and monitoring of MGUS patients.
  • Recent models (PANGEA, iSTOP) provide risk stratification for progression to multiple myeloma.

Guideline-Based Recommendations

Diagnosis

    Management

    • Regular monitoring of serum protein levels and clinical symptoms; treatment only if there is organ involvement or MGCS.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Focus on monitoring unless clinical symptoms or organ damage arise; specify criteria for intermediate to high-risk features.

        Clinical Best Practices

        • Educate patients about recognizing symptoms of progression to multiple myeloma.

        References

        Original Source(s)

        A Comprehensive Review of Monoclonal Gammopathy of Undetermined Significance

        • by Kimberly Noonan, Kevin Brigle, Charise Gleason, Carrie Bellerive, Mary Steinbach, Deborah Doss

        • March 4, 2026

        Related Content

        Biochemical Tumor Markers: Are New Testing Guidelines Fit for Purpose?

        CLSI guidance achieves technical excellence but has some questionable omissions, says Mustafa Barbhuiya

        Merging evans syndrome with mucopolysaccharidosis type II: a case report

        Toni Choueiri, MD discusses a novel HIF-2alpha inhibitor called casdatifan

        Results show it was well-tolerated and showed promising early clinical activity in heavily pretreated patients with clear cell renal cell carcinoma. 

        • February 26, 2025

        • 1 min